Metformin and Colorectal Cancer

被引：42

作者：

Higurashi, Takuma ^{[1
]}

Nakajima, Atsushi ^{[1
]}

机构：

[1] Yokohama City Univ, Sch Med, Dept Gastroenterol & Hepatol, Yokohama, Kanagawa, Japan

来源：

FRONTIERS IN ENDOCRINOLOGY | 2018年 / 9卷

基金：

日本学术振兴会;

关键词：

metfromin; colorectal cancer; chemoprevention; epidemiology; basic research; review; clinical trials; ABERRANT CRYPT FOCI; TYPE-2; DIABETES-MELLITUS; REDUCED RISK; COLON-CANCER; DOUBLE-BLIND; PREVENTION; COHORT; MTOR; CHEMOPREVENTION; THERAPY;

D O I：

10.3389/fendo.2018.00622

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Colorectal Cancer (CRC) is one of the most frequently encountered neoplasms in humans. The incidence of CRC has been increasing and new strategies for prevention, including chemoprevention, are required to lower its incidence and associated mortality. Metformin is a biguanide compound commonly used for the treatment of diabetes mellitus. Many recent basic research, epidemiological and clinical trial studies have indicated that metformin has benefits not only in diabetes treatment, but also in lowering the risk of developing cancer (including CRC). These studies indicate that metformin may be a candidate chemoprevention agent for CRC. This review article shall discuss the present evidence of metformin treatment and CRC, as well as outline our challenge in the investigation of metformin use in chemoprevention therapy for colorectal tumors.

引用

页数：7

共 58 条

[31] Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals
Lee, Meei-Shyuan
Hsu, Chih-Cheng
Wahlqvist, Mark L.
Tsai, Hsin-Ni
Chang, Yu-Hung
Huang, Yi-Chen
[J]. BMC CANCER, 2011, 11
[32] New Users of Metformin Are at Low Risk of Incident Cancer A cohort study among people with type 2 diabetes
Libby, Gillian
Donnelly, Louise A.
Donnan, Peter T.
Alessi, Dario R.
Morris, Andrew D.
Evans, Josie M. M.
[J]. DIABETES CARE, 2009, 32 (09) : 1620 - 1625
[33] Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer
Lieberman, David A.
Rex, Douglas K.
Winawer, Sidney J.
Giardiello, Francis M.
Johnson, David A.
Levin, Theodore R.
[J]. GASTROENTEROLOGY, 2012, 143 (03) : 844 - 857
[34] Clinically confirmed type 2 diabetes Mellitus and colorectal cancer risk: A population-based, retrospective cohort study
Limburg, Paul J.
Vierkant, Robert A.
Fredericksen, Zachary S.
Leibson, Cynthia L.
Rizza, Robert A.
Gupta, Amit K.
Ahlquist, David A.
Melton, Lee J., III
Sellers, Thomas A.
Cerhan, James R.
[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (08) : 1872 - 1879
[35] Association between Gastroenterological Malignancy and Diabetes Mellitus and Anti-Diabetic Therapy: A Nationwide, Population-Based Cohort Study
Lin, Chien-Ming
Huang, Hui-Ling
Chu, Fang-Ying
Fan, Hueng-Chuen
Chen, Hung-An
Chu, Der-Ming
Wu, Li-Wei
Wang, Chung-Ching
Chen, Wei-Liang
Lin, Shih-Hua
Ho, Shinn-Ying
[J]. PLOS ONE, 2015, 10 (05):
[36] MTOR, translation initiation and cancer
Mamane, Y.
Petroulakis, E.
LeBacquer, O.
Sonenberg, N.
[J]. ONCOGENE, 2006, 25 (48) : 6416 - 6422
[37] AMPK and cell proliferation - AMPK as a therapeutic target for atherosclerosis and cancer
Motoshima, Hiroyuki
Goldstein, Barry J.
Igata, Motoyuki
Araki, Eiichi
[J]. JOURNAL OF PHYSIOLOGY-LONDON, 2006, 574 (01): : 63 - 71
[38] The challenges for cancer chemoprevention
Penny, Lewis K.
Wallace, Heather M.
[J]. CHEMICAL SOCIETY REVIEWS, 2015, 44 (24) : 8836 - 8847
[39] Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects
Pierotti, M. A.
Berrino, F.
Gariboldi, M.
Melani, C.
Mogavero, A.
Negri, T.
Pasanisi, P.
Pilotti, S.
[J]. ONCOGENE, 2013, 32 (12) : 1475 - 1487
[40] PRETLOW TP, 1991, CANCER RES, V51, P1564

← 1 2 3 4 5 6 →